Tamibarotene
( DrugBank: Tamibarotene / KEGG DRUG: Tamibarotene )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 26 | HTLV-1-associated myelopathy | 1 |
| 67 | Polycystic kidney disease | 2 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
26. HTLV-1-associated myelopathy
Clinical trials : 33 / Drugs : 60 - (DrugBank : 31) / Drug target genes : 33 - Drug target pathways : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
67. Polycystic kidney disease
Clinical trials : 251 / Drugs : 278 - (DrugBank : 69) / Drug target genes : 97 - Drug target pathways : 182
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
96. Crohn disease
Clinical trials : 2,888 / Drugs : 1,678 - (DrugBank : 247) / Drug target genes : 193 - Drug target pathways : 234
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|